ABBOTT INDIA LIMITED
- Country
- 🇮🇳India
- Ownership
- Private
- Established
- 1888-01-01
- Employees
- 73K
- Market Cap
- $7.5B
- Website
- http://www.abbott.com
A Study of ABT-751 in Patients With Recurrent Breast Cancer After Taxane (Taxol or Taxotere) Therapy.
- Conditions
- First Posted Date
- 2003-06-23
- Last Posted Date
- 2007-11-29
- Lead Sponsor
- Abbott
- Target Recruit Count
- 40
- Registration Number
- NCT00063102
- Locations
- 🇺🇸
Oncology-Hematology Group of South Florida, Miami, Florida, United States
🇺🇸Clinical Research Network, Inc., Plantation, Florida, United States
🇺🇸Indiana University Cancer Center Section of of Hemtology/Oncology Indiana Cancer Pavilion, Indianapolis, Indiana, United States
Evaluate the Survival Benefits of Zemplar Versus Calcijex in Subjects w/ Stage V Chronic Kidney Disease on Hemodialysis
- Conditions
- First Posted Date
- 2003-06-13
- Last Posted Date
- 2006-08-02
- Lead Sponsor
- Abbott
- Target Recruit Count
- 2200
- Registration Number
- NCT00062699
- Locations
- 🇺🇸
Gambro Healthcare - Los Angeles, Los Angeles, California, United States
🇺🇸Paul Light, University of Maryland, Baltimore, Maryland, United States
🇺🇸Johns Hopkins University, Baltimore, Maryland, United States
Study Evaluating the Safety and Efficacy of ABT-510 in Subjects With Locally Advanced or Metastatic Soft Tissue Sarcoma
- Conditions
- First Posted Date
- 2003-06-04
- Last Posted Date
- 2007-11-29
- Lead Sponsor
- Abbott
- Target Recruit Count
- 88
- Registration Number
- NCT00061659
- Locations
- 🇺🇸
Virginia G. Piper Cancer Center, Scottsdale, Arizona, United States
🇺🇸Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸Cancer Therapy and Research Center, San Antonio, Texas, United States
Study Evaluating the Safety and Effectiveness of ABT-510 in Subjects With Refractory Lymphoma
- Conditions
- First Posted Date
- 2003-06-04
- Last Posted Date
- 2007-08-15
- Lead Sponsor
- Abbott
- Target Recruit Count
- 67
- Registration Number
- NCT00061672
- Locations
- 🇺🇸
Arch Medical Services, INC., St. Louis, Missouri, United States
🇺🇸Hematology Oncology Associates, San Antonio, Texas, United States
🇺🇸Raleigh Hematology Oncology Clinic, Cary, North Carolina, United States
Safety and Effectiveness of ABT-510 Plus Combination Chemotherapy in Subjects With Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- First Posted Date
- 2003-06-04
- Last Posted Date
- 2007-08-14
- Lead Sponsor
- Abbott
- Target Recruit Count
- 25
- Registration Number
- NCT00061646
- Locations
- 🇺🇸
University of Wisconsin, Madison,, Wisconsin, United States
🇺🇸The West Cancer Clinic, Memphis, Tennessee, United States
🇺🇸Oncology-Hematology Group of South Florida, Miami, Florida, United States
An Inpatient Study of the Effectiveness and Safety of Depakote ER in the Treatment of Mania/Bipolar Disorder
- Conditions
- First Posted Date
- 2003-05-16
- Last Posted Date
- 2006-08-04
- Lead Sponsor
- Abbott
- Target Recruit Count
- 370
- Registration Number
- NCT00060905
- Locations
- 🇺🇸
Brentwood Research Inst., Shreveport, Louisiana, United States
🇺🇸AVI Clinical Research, Torrance, California, United States
🇺🇸Comprehensive Neuroscience of SCA, Cerritos, California, United States
Study of a 6-Month Sustained-Release Formulation of Leuprolide Acetate in Prostate Cancer
- First Posted Date
- 2003-03-21
- Last Posted Date
- 2008-09-17
- Lead Sponsor
- Abbott
- Target Recruit Count
- 164
- Registration Number
- NCT00056654
- Locations
- 🇺🇸
Urology Associates of Central California, Fresno, California, United States
🇺🇸San Diego Uro-Research, San Diego, California, United States
🇺🇸West Side Veteran Administration Medical Center, Chicago, Illinois, United States
A Study of the Human Anti-TNF Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn's Disease
- Conditions
- First Posted Date
- 2003-03-06
- Last Posted Date
- 2006-08-15
- Lead Sponsor
- Abbott
- Target Recruit Count
- 300
- Registration Number
- NCT00055523
- Locations
- 🇺🇸
Clinical Pharmacology Study Group, Worcester, Massachusetts, United States
🇺🇸Mayo Clinic and Mayo Foundation, Rochester, Minnesota, United States
🇺🇸Northwest Gastroenterology, Bellevue, Washington, United States
Remission in Subjects With Crohn's Disease, 1 Year Phase
- First Posted Date
- 2003-03-05
- Last Posted Date
- 2011-04-11
- Lead Sponsor
- Abbott
- Target Recruit Count
- 276
- Registration Number
- NCT00055497
- Locations
- 🇺🇸
Northwest Gastroenterologists, S.C., Arlington Heights, Illinois, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Wake Research Associates, Weston, Florida, United States
Safety and Effectiveness of Zemplar Injection in Decreasing iPTH Levels in Pediatric ESRD Subjects on Hemodialysis
- Conditions
- First Posted Date
- 2003-02-03
- Last Posted Date
- 2006-08-02
- Lead Sponsor
- Abbott
- Target Recruit Count
- 28
- Registration Number
- NCT00053547
- Locations
- 🇺🇸
Medical College of Wisconsin, Milwaukee, Wisconsin, United States
🇺🇸Texas Children's Hospital, Houston, Texas, United States
🇺🇸Miami Children's Hospital, Miami, Florida, United States